From October 1, 2023 to December 31, 2023, the company has repurchased 5,452,563 shares, representing 4.13% for $250 million. With this, the company has completed the repurchase of 17,998,609 shares, representing 13.25% for $750.03 million under the buyback announced on December 9, 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.91 USD | +0.23% | +3.47% | +7.98% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.98% | 5.07B | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on December 9, 2021.